SX-517

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H407477

CAS#: 1240494-13-6

Description: SX-517 is a potent noncompetitive boronic acid CXCR1/2 antagonist. SX-517 inhibited CXCL1-induced Ca(2+) flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca(2+) flux induced by C5a, fMLF, or PAF. SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.


Chemical Structure

img
SX-517
CAS# 1240494-13-6

Theoretical Analysis

Hodoodo Cat#: H407477
Name: SX-517
CAS#: 1240494-13-6
Chemical Formula: C19H16BFN2O3S
Exact Mass: 382.10
Molecular Weight: 382.216
Elemental Analysis: C, 59.71; H, 4.22; B, 2.83; F, 4.97; N, 7.33; O, 12.56; S, 8.39

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SX-517; SX 517; SX517.

IUPAC/Chemical Name: 2-[5-(4-Fluoro-phenylcarbamoyl)-pyridin-2-ylsulfanylmethyl]-phenylboronic acid

InChi Key: VZRIHFZJVIOJBE-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H16BFN2O3S/c21-15-6-8-16(9-7-15)23-19(24)13-5-10-18(22-11-13)27-12-14-3-1-2-4-17(14)20(25)26/h1-11,25-26H,12H2,(H,23,24)

SMILES Code: OB(C1=CC=CC=C1CSC2=NC=C(C(NC3=CC=C(F)C=C3)=O)C=C2)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2).

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 382.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schuler AD, Engles CA, Maeda DY, Quinn MT, Kirpotina LN, Wicomb WN, Mason SN,
Auten RL, Zebala JA. Boronic acid-containing aminopyridine- and
aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous
solubility and oral bioavailability. Bioorg Med Chem Lett. 2015 Sep
15;25(18):3793-7. doi: 10.1016/j.bmcl.2015.07.090. Epub 2015 Jul 30. PubMed PMID:
26248802; PubMed Central PMCID: PMC4564001.


2: Maeda DY, Peck AM, Schuler AD, Quinn MT, Kirpotina LN, Wicomb WN, Fan GH,
Zebala JA. Discovery of
2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid
(SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem.
2014 Oct 23;57(20):8378-97. doi: 10.1021/jm500827t. Epub 2014 Oct 8. PubMed PMID:
25254640; PubMed Central PMCID: PMC4207547.